Shopping Cart
Remove All
Your shopping cart is currently empty
Glenzocimab (Synonyms: ACT017)
Catalog No. T77442 Copy Product Info
🥰Excellent
Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.
Glenzocimab
Copy Product Info🥰Excellent
Catalog No. T77442
Synonyms ACT017
Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.
Glenzocimab
Cas No. 2101829-58-5
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | - | In Stock | |
| 5 mg | $589 | - | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | $1,470 | - | In Stock | |
| 50 mg | $1,980 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:100% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis. |
| Targets&IC50 | GPVI-Fc:1.37 μg/mL |
| In vitro | Inhibited the binding of GPVI-Fc to collagen immobilized on microtiter plates, glenzocimab (0-100,000 ng/mL) demonstrated an IC50 of 1.37 μg/mL[2]. |
| In vivo | Glenzocimab ( 1-8 mg / kg ; i.v. ) inhibited collagen-induced platelet aggregation in cynomolgus monkeys [ 2 ]. |
| Synonyms | ACT017 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | GP6/Glycoprotein-6 |
| Molecular Weight | 48.29 kDa |
| Cas No. | 2101829-58-5 |
| Isotype | Human IgG1-CH1 kappa |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Keywords
Preview
Related Tags: buy Glenzocimab | purchase Glenzocimab | Glenzocimab cost | order Glenzocimab | Glenzocimab in vivo | Glenzocimab in vitro | Glenzocimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.